April 2011 in “Cancer Research” 20(S)-Protopanaxadiol-aglycone may help prevent and treat prostate cancer by reducing androgen receptor activity.
24 citations
,
October 2018 in “JAAD Case Reports” A woman's eyelash regrowth was successful using tofacitinib solution for alopecia areata.
January 2025 in “International Journal of Dermatology” Tofacitinib improved hair and nail conditions in a teen with alopecia areata.
May 2008 in “Trends in Urology Gynaecology & Sexual Health” Loop diuretics may double bone loss in elderly men, finasteride lowers prostate cancer risk but may increase high-grade tumors, abarelix reduces testosterone quickly, and transdermal testosterone offers minimal sexual benefit for women.
July 2024 in “Medical alphabet” JAK inhibitors like tofacitinib may effectively treat alopecia in children without major side effects.
January 2025 in “Biochemical Pharmacology” Peficitinib can turn human fibroblasts into cells that help grow hair.
November 2024 in “Gynecological Endocrinology” The article's findings are uncertain and should be viewed with caution.
January 1975 in “NJEA Review” The drug showed promise in treating renal cell carcinoma with manageable side effects.
20 citations
,
April 2006 in “Dermatologic Clinics” Antiandrogen therapies are beneficial for treating skin and hair conditions related to androgen levels.
2 citations
,
January 2014 in “Advanced Biomedical Research” Oral isotretinoin and cyproterone compound are equally effective for treating acne in women with cutaneous hyperandrogenism.
November 2025 in “Acta Dermato Venereologica” Effective immunomodulatory treatments and a personalized approach are crucial for managing severe folliculitis decalvans.
5 citations
,
September 2014 in “Journal of Pharmaceutical Sciences”
5 citations
,
December 2011 in “Drug Research” CB-03-01 is a promising skin cream for treating hormone-related skin problems without causing harmful body-wide effects.
May 2015 in “Journal of The American Academy of Dermatology” Mycophenolate mofetil may improve symptoms and stop hair loss in Lichen planopilaris, but more research is needed.
March 2014 in “The Journal of Urology” Finasteride increases CD8+ T cells in BPH tissues.
Dutasteride is more effective and better tolerated than finasteride for hair loss treatment.
14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
January 2024 in “American journal of clinical dermatology” Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
September 2002 in “Oncology Times” Promising cancer treatments were found, but the manufacturer closed.
42 citations
,
February 1998 in “The Journal of Steroid Biochemistry and Molecular Biology” PNU 157706 is a more effective treatment than finasteride for conditions caused by DHT, like enlarged prostate and hair loss.
24 citations
,
March 2022 in “Journal of the American Academy of Dermatology” Adalimumab improved folliculitis decalvans in most patients.
November 2025 in “Turkish Journal of Dermatology” Both baricitinib and tofacitinib effectively reduce alopecia areata severity, with tofacitinib showing more improvement over longer use.
June 2026 in “The Journal of Sexual Medicine” Finasteride may be linked to more psychiatric issues than dutasteride, but a definite cause isn't proven.
November 2023 in “Journal of Pakistan Society of Internal Medicine.” Methotrexate is effective for rheumatoid arthritis but can cause side effects.
December 2023 in “Biointerface Research in Applied Chemistry” Stiripentol shows promise as a potential treatment for androgen-related diseases but needs more testing.
5 citations
,
February 2024 in “Clinical Pharmacokinetics” A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.
April 2016 in “Journal of The American Academy of Dermatology” Finasteride effectively treated hidradenitis suppurativa.
Cyproterone acetate is used for topical treatment of diseases dependent on male hormones.
October 2024 in “The American Journal of Gastroenterology” Upadacitinib improved both Crohn's ileitis and alopecia universalis in a patient.
September 2023 in “Journal of the American Academy of Dermatology” Oral Janus kinase inhibitors are effective for treating alopecia areata in adults.